We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-3.73%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$279M
AUM Growth
+$25M
Cap. Flow
-$440M
Cap. Flow %
-158.03%
Top 10 Hldgs %
59.15%
Holding
68
New
18
Increased
13
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
RCM
R1 RCM Inc. Common Stock
RCM
+$18.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$14.2M
3
HCA icon
HCA Healthcare
HCA
+$13.7M
4
CRL icon
Charles River Laboratories
CRL
+$10.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$9.66M

Top Sells

Rank Stock Value
1
TAK icon
Takeda Pharmaceutical
TAK
+$14.5M
2
IRTC icon
iRhythm Holdings
IRTC
+$8.18M
3
AVDR
Avedro, Inc Common Stock
AVDR
+$7.03M
4
HUM icon
Humana
HUM
+$6.7M
5
EHC icon
Encompass Health
EHC
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Industrials 7.62%
3 Technology 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
1
DELISTED
R1 RCM Inc. Common Stock
RCM
$21.2M 7.62%
2,378,963
+1,548,154
+186% +$18.3M
ZBH icon
2
Zimmer Biomet
ZBH
$18.2B
$20.9M 7.51%
157,071
+44,150
+39% +$5.7M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$19.6M 7.05%
+66,200
New +$19.6M
HCA icon
4
HCA Healthcare
HCA
$87.2B
$18M 6.47%
149,755
+106,132
+243% +$13.7M
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$16.5M 5.91%
989,436
+360,200
+57% +$4.98M
LH icon
6
Labcorp
LH
$25B
$14.9M 5.37%
103,576
+7,080
+7% +$1.03M
BMY icon
7
Bristol-Myers Squibb
BMY
$133B
$14.8M 5.31%
291,925
+205,628
+238% +$9.66M
JNJ icon
8
Johnson & Johnson
JNJ
$618B
$13.9M 4.99%
+107,413
New +$14.2M
PRAH
9
DELISTED
PRA Health Sciences, Inc.
PRAH
$12.6M 4.52%
126,809
+29,609
+30% +$2.94M
ABBV icon
10
AbbVie
ABBV
$443B
$12.3M 4.4%
162,007
+72,999
+82% +$5M
CI icon
11
Cigna
CI
$73.7B
$10.9M 3.93%
72,109
+10,519
+17% +$1.71M
CRL icon
12
Charles River Laboratories
CRL
$11.2B
$9.93M 3.56%
+74,986
New +$10.1M
COR icon
13
Cencora
COR
$60.6B
$8.69M 3.12%
105,501
+31,998
+44% +$2.75M
ZTS icon
14
Zoetis
ZTS
$32.4B
$7.6M 2.73%
+60,999
New +$7.36M
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
$6.22M 2.23%
301,391
-70,588
-19% -$1.68M
ELV icon
16
Elevance Health
ELV
$81.5B
$6.16M 2.21%
+25,657
New +$7.03M
BDX icon
17
Becton Dickinson
BDX
$45.6B
$5.58M 2%
+22,613
New +$5.58M
IART icon
18
Integra LifeSciences
IART
$1.29B
$5.06M 1.82%
84,225
+41,398
+97% +$2.47M
HAE icon
19
Haemonetics
HAE
$3.89B
$4.11M 1.48%
+32,594
New +$4.14M
SIEN
20
DELISTED
Sientra, Inc.
SIEN
$3.43M 1.23%
52,995
-75,591
-59% -$4.81M
SNY icon
21
Sanofi
SNY
$103B
$3.11M 1.12%
67,200
-53,414
-44% -$2.3M
NCNA
22
NuCana
NCNA
$5.49M
$2.79M 1%
+77
New +$3.39M
FATE icon
23
Fate Therapeutics
FATE
$286M
$2.59M 0.93%
+166,782
New +$3.2M
BIO icon
24
Bio-Rad Laboratories Class A
BIO
$8.71B
$2.3M 0.83%
6,910
+3,175
+85% +$1.04M
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.97M 0.71%
17,130
-1,080
-6% -$164K
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Endurant Capital Management held 68 positions worth $279M, up 9.9% from $254M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Endurant Capital Management withdrew a net $440M in Q3 2019, closing 19 positions and reducing 17 holdings. Its most notable exit was iRhythm Holdings, an estimated $8.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 77% a quarter earlier, followed by Industrials and Technology.

Against the trend, Endurant Capital Management opened a new position in Johnson & Johnson worth $13.9M.

  • Endurant Capital Management's largest Q3 2019 buy was Johnson & Johnson: 107,413 shares worth $13.9M.
  • Endurant Capital Management added most to R1 RCM Inc. Common Stock in Q3 2019, an estimated $18.3M increase.
  • Endurant Capital Management's biggest Q3 2019 reduction was Takeda Pharmaceutical, cutting an estimated $14.5M.
  • Endurant Capital Management fully exited iRhythm Holdings in Q3 2019, selling an estimated $8.18M.
  • Endurant Capital Management's ten largest holdings make up 59% of its $279M portfolio in Q3 2019.
  • Endurant Capital Management opened 18 new positions and closed 19 in Q3 2019.
  • Endurant Capital Management's portfolio value rose 9.9% quarter-over-quarter to $279M.

Based on Endurant Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.